

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number  
**WO 2004/000296 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/195**,  
A61P 11/06, 11/02, 11/00, 23/00, 25/06, 1/00

[GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0DP (GB).

(21) International Application Number:  
PCT/EP2003/006465

(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date: 19 June 2003 (19.06.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0214147.1 19 June 2002 (19.06.2002) GB

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **SB PHARMCO PUERTO RICO INC.** [US/US]; The Prentice Hall Corp System of P.R., Inc., c/o FGR Corporate Services, Inc., BBV Tower, 8th Floor, 254 Munoz Rivera Avenue, 00918 San Juan (PR).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BROUGHTON, Stuart, James** [GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0DP (GB). **GHARU, Rajinder, Kumar** [GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0DP (GB). **LEOW, Mark, Yuon, Tuck** [GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0DP (GB). **NEALE, Phillip, John**

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: (2S)-2-AMINO-4-{{[2-(ETHANIMIDOYLAMINO) ETHYL]THIO}BUTANOIC ACID, A NITRIC OXIDE SYNTHASE INHIBITOR, IN STABILIZED PHARMACEUTICAL DOSAGE FORMS



(1)

(57) Abstract: Pharmaceutical compositions comprising (2S)-2-amino-4-{{[2-(ethanimidoethyl)thio]butanoic acid: (Formula I); a pharmaceutically acceptable bulking agent and one or more antioxidants or chelating agents are described.

WO 2004/000296 A1


(2S)-2-AMINO-4-{[2-(ETHANIMIDOYLAMINO)ETHYL]THIO}BUTANOIC ACID, A NITRIC OXIDE SYNTHASE INHIBITOR, IN STABILIZED PHARMACEUTICAL DOSAGE FORMS

The present invention relates to novel pharmaceutical formulations of (2S)-2-amino-4-[[2-(ethanimidoethylamino)ethyl]thio]butanoic acid, to processes for their manufacture, and to their use in therapy.

Nitric oxide is the endogenous stimulator of the soluble guanylate cyclase enzyme and is involved in a number of biological actions. Excess nitric oxide production is also thought to be involved in a number of conditions, including septic shock and many inflammatory diseases. The biochemical synthesis of nitric oxide from L-arginine is catalysed by the enzyme NO synthase. Many inhibitors of NO synthase have been described and proposed for therapeutic use.

More recently, it has been an object in this field to provide NO synthase inhibitors displaying selectivity for either inducible NO synthase (iNOS) or neuronal NO synthase (nNOS) over endothelial NO synthase (eNOS).

Thus WO98/30537 describes selective NO synthase inhibitors of formula



or a salt, solvate, or physiologically functional derivative thereof.

Co-pending patent application number PCT/GB01/05596 (published as WO02/50021) describes a phosphate salt of (2S)-2-amino-4-[[2-(ethanimidoethylamino)ethyl]thio]butanoic acid, and solvates thereof, which has advantageous properties, in particular, being considerably less hygroscopic than, for example, the hydrochloride salts exemplified in WO98/30537.

We have found that (2S)-2-amino-4-[[2-(ethanimidoethylamino)ethyl]thio] butanoic acid, for example, in the form of its compound with phosphoric acid, exhibits incompatibility with standard pharmaceutical excipients conventionally used in the preparation of solid oral dosage forms such as tablets. This incompatibility results in increased degradation of the (2S)-2-amino-4-[[2-(ethanimidoethylamino)ethyl]thio]butanoic acid and reduced stability of the formulations. We have further found that these problems can be overcome by the addition to solid oral dosage forms comprising (2S)-2-amino-4-[[2-(ethanimidoethylamino)ethyl] thio] butanoic acid and conventional pharmaceutical excipients of an antioxidant and/or a chelating agent.

According to the present invention there is provided a pharmaceutical composition comprising (2S)-2-amino-4-[[2-(ethanimidoethylamino)ethyl]thio] butanoic acid, a

pharmaceutically acceptable bulking agent and one or more antioxidants or chelating agents.

For use in accordance with the present invention, the (2S)-2-amino-4-[[2-  
5 (ethanimidoylamino)ethyl]thio]butanoic acid will preferably be in the form of its compound with phosphoric acid, preferably in hydrated form. More preferably each molecule (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio]butanoic acid is associated with at least one molecule of water, such as 1, 2 or 3 water molecules, especially 1 or 3 water molecules, preferably 1 water molecule. Suitably, the (2S)-2-amino- 4-[[2-(ethanimidoylamino)ethyl]  
10 thio]butanoic acid comprises from about 0.1 to about 5 % by weight, preferably about 0.25 to about 2.5%, more preferably about 0.5 to about 1%, such as about 0.6%, based on the dry weight of the dosage form.

It will be appreciated by those skilled in the art that phosphoric acid exists in more than one  
15 form. The preferred form for use in the context of the present invention is orthophosphoric acid ( $\text{H}_3\text{PO}_4$ ).

Pharmaceutically acceptable bulking agents are inert substances that provide bulk and dilute the active ingredient when used in the compositions of the present invention. Suitable  
20 pharmaceutically acceptable bulking agents will be well known to the person skilled in the art and a non-limiting list of examples includes microcrystalline cellulose (available as, for example, Avicel<sup>TM</sup>), croscarmellose sodium, crospovidone, starch, calcium carboxymethylcellulose, silicified microcrystalline cellulose, magnesium oxide, tragacanth, dibasic calcium phosphate dihydrate, anhydrous dibasic calcium phosphate (available as, for  
25 example, Emcompress<sup>TM</sup>), tribasic calcium phosphate, calcium carbonate, magnesium carbonate, calcium sulfate, cellulose acetate, powdered cellulose, kaolin, polymethacrylates and talc. The pharmaceutically acceptable bulking agents may be used alone or in combination with each other. Preferred is Avicel<sup>TM</sup>, such as, for example, Avicel<sup>TM</sup> PH101, Avicel<sup>TM</sup> PH102, Avicel<sup>TM</sup> PH112, Avicel<sup>TM</sup> PH113 and Avicel<sup>TM</sup> PH200, starch, and mixtures  
30 thereof. Particularly preferred pharmaceutically acceptable bulking agents for use in the present invention are Avicel<sup>TM</sup> PH101, starch 1500 and mixtures thereof.

Suitably, the pharmaceutically acceptable bulking agents comprise from about 80 to about 99.5 % by weight, preferably about 90 to about 99 %, more preferably about 95 to about  
35 98.3 %, based on the dry weight of the dosage form.

Suitable antioxidants and chelating agents for use in the compositions of the present invention will be pharmaceutically acceptable and include, for example, organic acids such as ethylenediaminetetraacetic acid (EDTA), ascorbic acid, malic acid, citric acid and fumaric  
40 acid, and salts and esters thereof such as, for example, sodium ascorbate and propyl gallate, salts of inorganic acids such as, for example, sodium metabisulfite, alcohols such as, for example, maltol and alpha tocopherol and aromatic compounds such as, for example, butylated hydroxyanisole and butylated hydroxytoluene. Preferred are EDTA, malic acid and ascorbic acid and mixtures thereof, especially EDTA, malic acid and mixtures thereof.

Suitably, the antioxidant, chelating agent, or mixture thereof comprises from about 0.005 to about 5 % by weight, preferably about 0.01 to about 2.5%, more preferably about 0.05 to about 2%, such as about 0.1%, based on the dry weight of the dosage form.

5 Thus, in a further embodiment of the present invention, there is provided a pharmaceutical composition as hereinbefore described wherein the (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio]butanoic acid comprises from about 0.1 to about 5% by weight, preferably about 0.25 to about 2.5%, more preferably about 0.5 to 1%, especially about 0.6%, the pharmaceutically acceptable bulking agent comprises from about 80 to about 99.5% by  
10 weight, preferably about 90 to about 99%, more preferably about 95 to about 98.3%, and the antioxidant, chelating agent, or mixture thereof comprises from about 0.005 to about 5% by weight, preferably about 0.01 to about 2.5%, more preferably about 0.05 to about 2%, especially about 0.1%, based on the dry weight of the dosage form.

15 In a further embodiment of the present invention, there is provided a pharmaceutical composition as hereinbefore described wherein the (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio]butanoic acid is in the form of its compound with phosphoric acid, preferably in hydrated form, more preferably as the monohydrate or the trihydrate, the pharmaceutically acceptable bulking agent comprises Avicel™, preferably Avicel™ PH101, Avicel™ PH102,  
20 Avicel™ PH112, Avicel™ PH113 or Avicel™ PH200, or starch, or, more preferably, a mixture of Avicel™ and starch, the antioxidant, chelating agent, or mixture thereof comprises EDTA, malic acid or ascorbic acid, or a mixture of EDTA and malic acid or a mixture of EDTA and ascorbic acid. Particularly preferred are compositions comprising (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio]butanoic acid compound with phosphoric acid, 1:1,  
25 monohydrate, Avicel™ PH101, optionally starch 1500, and EDTA, malic acid or a mixture of EDTA and malic acid.

In addition to the ingredients described above, the pharmaceutical composition of the present invention may further comprise pharmaceutically acceptable excipients such as  
30 binding agents (e.g. pregelatinised starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose) and lubricants (e.g. stearic acid, silicon dioxide, magnesium stearate, talc, sodium benzoate and hydrogenated vegetable oil).

Many drug substances have an inherently bitter taste. The unpleasant taste that is  
35 sometimes associated with oral administration of a composition comprising (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio]butanoic acid may be substantially eliminated by the use of a film coat on the solid core. The solid core comprises (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio]butanoic acid.

40 Accordingly, in one embodiment, the present invention provides a pharmaceutical composition as hereinbefore described in the form of a tablet which is film-coated.

The film coating may suitably comprise a polymer. Suitable polymers will be well known to the person skilled in the art and a non-limiting list of examples includes cellulose ethers, for

example, hydroxypropylmethylcellulose, hydroxypropylcellulose or methylcellulose, and copolymers of methacrylic acid and methyl methacrylate.

5 The total film coating solids are generally applied to the solid dosage form, for example the tablet core, in an amount of from about 0.5 to 10 % by weight, preferably about 1 to about 4%, more preferably about 2 to about 3%, based on the dry weight of the dosage form.

10 The film coating may additionally comprise any pharmaceutically acceptable colourants or opacifiers including water soluble dyes, aluminium lakes of water soluble dyes and inorganic pigments such as titanium dioxide and iron oxide.

The film coating may also contain one or more plasticising agents conventionally used in polymeric film coatings, for example, polyethylene glycol, propylene glycol, dibutyl sebacate, mineral oil, sesame oil, diethyl phthalate and triacetin. Proprietary film coating materials,  
15 such as Opaspray and Opadry, obtainable from Colorcon Ltd., UK, may be used.

The taste of oral compositions may also be improved by the use of flavouring and/or sweetening agents. Suitable flavouring agents will be well known to the person skilled in the art and a non-limiting list of examples includes lemon, orange, grapefruit, vanilla, caramel,  
20 butterscotch, hazelnut or mint flavouring. Suitable sweetening agents for use in the compositions of the invention will be well known to the person skilled in the art and a non-limiting list of examples includes sucrose, saccharin, cyclamic acid and alkali or alkali earth metal salts thereof, mannitol, acesulfame-K, stevioside, thaumatin and aspartame. The flavouring and/or sweetening agents may be used alone or in combination with each other.

25 As mentioned above, the compound of formula (I) is an inhibitor of NO synthase.

In a further aspect, the present invention provides a pharmaceutical composition for oral administration as hereinbefore described for use in the treatment of clinical conditions for  
30 which an inhibitor of NO synthase is indicated, in particular an inhibitor of iNOS. Such conditions include inflammatory conditions, shock states, immune disorders, disorders of gastrointestinal motility and diseases of the central nervous system including migraine and metabolic disorders including dyslipidemia.

35 By shock states is meant those resulting from overproduction of NO, such as septic shock, haemorrhagic shock, traumatic shock, or shock caused by fulminant hepatic failure or by therapy with cytokines such as TNF, IL-1 and IL-2 or therapy with cytokine-inducing agents, for example 5,6-dimethylxanthenone acetic acid.

40 Examples of inflammatory conditions and immune disorders include those of the joint, particularly arthritis (e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure), or the gastrointestinal tract (e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel diseases, gastritis and mucosal inflammation resulting from infection, the enteropathy provoked by non-steroidal anti-inflammatory drugs), of the airways (e.g. adult respiratory

distress syndrome, asthma, cystic fibrosis, upper respiratory tract inflammatory disease (e.g. rhinitis such as allergic rhinitis) or chronic obstructive pulmonary disease), of the heart (e.g. myocarditis), of nervous tissue (e.g. multiple sclerosis), of the pancreas (e.g. diabetes melitus and complications thereof), of the kidney (e.g. glomerulonephritis), of the skin (e.g. dermatitis, psoriasis, eczema, urticaria), of the eye (e.g. glaucoma) as well as of transplanted organs (e.g. rejection) and multi-organ diseases (e.g. systemic lupus erythematosus) and inflammatory sequelae of viral or bacterial infections.

Furthermore, there is evidence for overproduction of NO by iNOS in atherosclerosis and following hypoxic or ischaemic insults (with or without reperfusion), for example in the brain or in ischaemic heart disease.

Disorders of gastrointestinal motility include ileus, for example post-operative ileus and ileus during sepsis.

By diseases of the central nervous system is meant those for which overproduction of NO is implicated, for example migraine, psychosis, anxiety, schizophrenia, sleep disorders, cerebral ischaemia, CNS trauma, epilepsy, multiple sclerosis, AIDS dementia, chronic neurodegenerative disease (e.g. Lewy Body Dementia, Huntington's disease, Parkinson's disease, or Alzheimer's disease) and acute and chronic pain, and conditions in which non-adrenergic non-cholinergic nerves may be implicated such as priapism, obesity and hyperphagia.

Examples of acute pain include musculoskeletal pain, post operative pain and surgical pain. Examples of chronic pain include chronic inflammatory pain (e.g. rheumatoid arthritis and osteoarthritis), neuropathic pain (e.g. post herpetic neuralgia, diabetic neuropathies associated with diabetes, trigeminal neuralgia, pain associated with functional bowel disorders, e.g. irritable bowel syndrome, non cardiac chest pain and sympathetically maintained pain) and pain associated with cancer and fibromyalgia.

Overproduction of NO is implicated in metabolic disorders through its effect on lipoprotein lipase activity causing hypertriglyceridemia. Selective inhibitors of iNOS will be useful in metabolic conditions where NO over-production is implicated, such as dyslipidaemia.

Furthermore, inhibition of NO synthase may be of advantage in preventing the lymphocyte loss associated with HIV infection, in increasing the radiosensitivity of tumours during radiotherapy and in reducing tumour growth, tumour progression, angiogenesis, and metastasis.

It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms.

Accordingly, the present invention provides a method for the treatment of a clinical condition in a mammal, such as a human, for which an inhibitor of nitric oxide synthase, for example,

an iNOS inhibitor is indicated, which comprises oral administration of a pharmaceutical composition as hereinbefore described. In particular, the present invention provides a method for the treatment of an inflammatory and/or immune disorder, such as arthritis, allergic rhinitis, COPD or asthma. In a further preferred aspect the present invention  
5 provides a method for the prophylaxis or treatment of a clinical condition selected from pain, migraine, ileus and irritable bowel syndrome.

According to a further aspect of the invention, there is provided the use of a pharmaceutical composition for oral administration as hereinbefore described in the manufacture of a  
10 medicament for treating conditions for which an inhibitor of nitric oxide synthase, for example, an iNOS inhibitor is indicated. In particular, the present invention provides the use of a pharmaceutical composition for oral administration as hereinbefore described in the manufacture of a medicament for treating an inflammatory and/or immune disorder, such as arthritis, allergic rhinitis, COPD or asthma, pain, migraine, ileus or irritable bowel syndrome.

15 In the alternative, there is also provided a pharmaceutical composition for oral administration as hereinbefore described for use in medical therapy, particularly for use in the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which an inhibitor of nitric oxide synthase, for example an iNOS inhibitor, is indicated. In particular, there is  
20 provided a pharmaceutical composition for oral administration as hereinbefore described for the treatment of an inflammatory and/or immune disorder, such as arthritis, allergic rhinitis, COPD or asthma, pain, migraine, ileus or irritable bowel syndrome.

The amount of (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio] butanoic acid which is  
25 required to achieve a therapeutic effect will, of course, vary with the route of administration, the subject under treatment, and the particular disorder or disease being treated. Typically a dose of from 0.001 to 200mg/kg per day, preferably 0.01 to 20mg/kg per day may be employed. The dose range for adult humans is generally from 0.1mg to 10g/day and preferably 1mg to 1g/day.

30 For the preparation of compositions according to the invention, the active ingredient, the antioxidant and/or chelating agent and optional additional excipients such as lubricants, etc. may be blended with the pharmaceutically acceptable bulking agent. If desired, one or more of the components of this powder blend may be granulated. A process of, for example, dry  
35 granulation, wet granulation or solvent granulation may optionally be used. Dry granulation is generally preferred. Tablets may be prepared, for example, by compression of the powder blend. Capsules may be prepared, for example, by filling of the powder blend into suitable capsule shells.

40 The solid dosage form may be film-coated using a suspension comprising a suitable polymer in a suitable solvent. The preferred solvent for the film coating components is purified water but various classes of organic solvents commonly used in this art such as alcohols, ketones, ethers and chlorinated hydrocarbons, for example ethanol, acetone, dichloromethane and the like, may also be used. The solvent does not appear in the final product.

Herein, the term "active ingredient" means (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio] butanoic acid and pharmaceutically acceptable salts and solvates thereof.

- 5 The invention is illustrated by the following non-limiting examples wherein Compound A is (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio] butanoic acid, compound with phosphoric acid, monohydrate.

#### 10 Example 1

Direct Compression Formulation for (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio] butanoic acid, compound with phosphoric acid, monohydrate (Compound A)

##### Formula 1

15

Component	Percent w/w
Compound A	0.62
EDTA	0.1
Avicel PH101	98.28
Silicon Dioxide	0.5
Magnesium Stearate	0.5
Total Tablet Weight	250mg

##### Dry Granulation Method

The components other than magnesium stearate are weighed from bulk containers, sieved using either hand held screens or a Ytron-Quadro Comil 197AS and deposited into a stainless-steel blending container. The components are blended for up to 30 minutes using a suitable blender, such as an Apex MPX, Fordertechnik FT or Glatt GPCG. The magnesium stearate is then added to the mixture and blending is continued for approximately 2 minutes. The lubricated blend is then compressed using a suitable rotary tablet press, such as a Unipress B/D. The tablets are coated using a film coater such as an Accelacota 10 or Glatt GC500.

##### Wet Granulation Method

The Compound A and EDTA (and/or, as appropriate, an antioxidant) are dissolved in a volume of water (approx. 2.5 to 3.0 litres) and sprayed onto bulk excipient particles (i.e. Avicel), granulated and dried using a mixer granulator, such as a PMA10. The dry granules are blended using a suitable blender, such as an Apex MPX or Fordertechnik FT with further Avicel, silicon dioxide and magnesium stearate. The lubricated blend is then compressed using a suitable rotary press, typically a Unipress B/D press.

The tablets are coated using a film coater such as an Accelacota 10 or Glatt GC500.

35

Formulations according to the following examples were similarly prepared:



**Example 2**

Component	Percent w/w
Compound A	0.62
Ascorbic acid	0.1
Avicel PH101	98.28
Silicon Dioxide	0.5
Magnesium Stearate	0.5
Total Tablet Weight	250mg

**Example 3**

5

Component	Percent w/w
Compound A	0.62
Malic acid	0.1
Avicel PH101	98.28
Silicon Dioxide	0.5
Magnesium Stearate	0.5
Total Tablet Weight	250mg

**Example 4**

Component	Percent w/w
Compound A	0.62
EDTA	0.1
Ascorbic acid	0.1
Avicel PH101	98.18
Silicon Dioxide	0.5
Magnesium Stearate	0.5
Total Tablet Weight	250mg

**10 Example 5**

Component	Percent w/w
Compound A	0.62
EDTA	0.1
Avicel PH101	58.28
Starch 1500	40.0
Silicon Dioxide	0.5
Magnesium Stearate	0.5
Total Tablet Weight	250mg

**Example 6**

Component	Percent w/w
Compound A	0.62
Ascorbic acid	0.1
Avicel PH101	58.28
Starch 1500	40.0
Silicon Dioxide	0.5
Magnesium Stearate	0.5
Total Tablet Weight	250mg

**Example 7**

5

Component	Percent w/w
Compound A	0.62
Malic acid	0.1
Avicel PH101	58.28
Starch 1500	40.0
Silicon Dioxide	0.5
Magnesium Stearate	0.5
Total Tablet Weight	250mg

**Example 8**

Component	Percent w/w
Compound A	0.62
EDTA	0.1
Ascorbic acid	0.1
Avicel PH101	58.18
Starch 1500	40.0
Silicon Dioxide	0.5
Magnesium Stearate	0.5
Total Tablet Weight	250mg

**Example 9**

Component	Percent w/w
Compound A	0.62
EDTA	0.1
Malic acid	0.1
Avicel PH101	58.18
Starch 1500	40.0
Silicon Dioxide	0.5
Magnesium Stearate	0.5
Total Tablet Weight	250mg

**5 STABILITY RESULTS**

1mg tablet formulations corresponding to Examples 1 – 8 (each tablet contains 1mg of (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio] butanoic acid) were prepared by dry granulation, essentially as described in Example 1 but mixing by hand using a pestle and mortar.

The impurity content of the formulations thus prepared was measured (initial time point) by high pressure liquid chromatography (HPLC). Samples of the formulations were stored at 40°C, 75% relative humidity and 50°C, ambient humidity for three months. The impurity content (greatest impurity and total impurities) was measured at 14 days, 1 month and 3 month time points. The HPLC system used was an Agilent 1100 HPLC system. Typical chromatographic conditions were:

Analytical column: Prodigy ODS 3 5µm 150x4.6mm  
20 Mobile Phase: 87:13 Aq Component (0.02M pot.dihydrogen orthophosphate/0.01M)  
Flow rate: 1.5ml/min  
Temp: 40degC  
Detection: UV @ 205nm  
25 Inj Vol: 10µL  
Approx. run time: 25 min

Moisture content of Compound A was determined using a Mitsubishi CA06 Moisture meter connected to a Mitsubishi VA06 Vaporiser

30 N2 flow: 200ml/min  
Stirrer speed: 5  
Delay time: 30secs  
Sensitivity: 0.1µg sec-1  
35 Temp: 135degC

Vapouriser cycle: 1-1-1

Back range time: 1 min

Samp boat removal time: 1 min

Samp boat cooling time: 1 min

5 Reagents Anode: Aquamicon AKX or AX (150ml)

Cathode: Aquamicon CXU (2 ampoules)

The results are shown in Table 1. The greatest chemical stability was seen for the formulations corresponding to Examples 3, 5 and 7.

10 Table 1

Formu- lation	Impurity Content													
	Greatest							Total						
	INT	DY14		MN1		MN3		INT	DY14		MN1		MN3	
		40/ 75	50/ Amb	40/ 75	50/ Amb	40/ 75	50/ Amb		40/ 75	50/ Amb	40/ 75	50/ Amb	40/ 75	50/ Amb
Ex 1	0.16	0.17	0.16	0.16	0.21	1.92	0.25	0.2	0.3	0.4	0.4	0.5	4.7	0.7
Ex 2	0.48	0.21	0.44	0.25	0.40	4.31	0.32	1.0	0.6	1.0	0.8	1.0	8.8	1.0
Ex 3	0.19	0.17	0.17	0.21	0.16	0.95	0.25	0.3	0.3	0.5	0.5	0.5	2.2	0.7
Ex 4	0.17	0.17	0.16	0.18	0.16	3.65	0.26	0.3	0.4	0.4	0.5	0.5	8.1	0.8
Ex 5	0.17	0.16	0.16	0.42	0.16	1.03	0.17	0.3	0.3	0.4	1.5	0.4	2.8	0.6
Ex 6	0.75	0.17	0.64	0.42	0.2	3.63	0.34	1.5	0.4	1.3	1.1	0.6	7.4	0.9
Ex 7	0.19	0.17	0.21	0.17	0.19	0.61	0.28	0.4	0.4	0.6	0.4	0.6	1.9	0.8
Ex 8	0.16	0.17	0.18	0.19	0.22	1.92	0.34	0.4	0.4	0.5	0.5	0.6	4.2	0.9

INT = initial time point

DY14 = day 14

15 MN1 = 1 month

MN3 = 3 months

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any novel feature or combination of features described herein. This may take the form of product, composition, process or use claims and may include, by way of example and without limitation, one or more of the following claims:

## Claims

1. A pharmaceutical composition comprising (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio] butanoic acid, a pharmaceutically acceptable bulking agent  
5 and one or more antioxidants or chelating agents.
2. A pharmaceutical composition as claimed in claim 1 wherein the (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio]butanoic acid is in the form of its (1:1) compound with phosphoric acid, or a solvate thereof.  
10
3. A pharmaceutical composition as claimed in claim 1 or claim 2 wherein the solvate is a hydrate.
4. A pharmaceutical composition as claimed in claim 3 wherein the hydrate is the  
15 monohydrate.
5. A pharmaceutical composition as claimed in claim 3 wherein the hydrate is the trihydrate.
- 20 6. A pharmaceutical composition as claimed in any of claims 1 to 5 wherein the (2S)-2-amino-4-[[2-(ethanimidoylamino)ethyl]thio]butanoic acid comprises from about 0.1 to about 5% by weight, the pharmaceutically acceptable bulking agent comprises from about 80 to about 99.5% by weight, and the antioxidant, chelating agent, or mixture thereof comprises from about 0.005 to about 5% by weight, based on the dry weight.  
25
7. A pharmaceutical composition as claimed in any of claims 1 to 6 wherein the antioxidants or chelating agents are selected from the group comprising EDTA, malic acid, ascorbic acid and mixtures thereof.
- 30 8. A pharmaceutical composition as claimed in any of claims 1 to 7 wherein the pharmaceutically acceptable bulking agent comprises microcrystalline cellulose, starch or a mixture thereof.
9. A method for the treatment or prophylaxis of a clinical condition in a mammal, such  
35 as a human, for which an inhibitor of nitric oxide synthase is indicated, which comprises administration of a pharmaceutical composition as claimed in any of claims 1 to 8.
10. A method as claimed in claim 9 wherein the clinical condition is selected from arthritis, asthma, rhinitis, chronic obstructive pulmonary disease, ileus, migraine, pain and  
40 irritable bowel syndrome.
11. A pharmaceutical composition as claimed in any of claims 1 to 8 for use in medical therapy.

12. A pharmaceutical composition as claimed in claim 11 for use in the treatment or prophylaxis of a clinical condition in a mammal, such as a human, for which an inhibitor of nitric oxide synthase is indicated.

5 13. A pharmaceutical composition as claimed in claim 12 wherein the clinical condition is selected from arthritis, asthma, rhinitis, chronic obstructive pulmonary disease, ileus, migraine, pain and irritable bowel syndrome.

14. Use of a pharmaceutical composition as claimed in any of claims 1 to 8 in the  
10 manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which an inhibitor of nitric oxide synthase is indicated.

15. Use according to claim 14 wherein the clinical condition is selected from arthritis, asthma, rhinitis, chronic obstructive pulmonary disease, ileus, migraine, pain and irritable  
15 bowel syndrome.

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/EP 03/06465

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/195 A61P11/06 A61P11/02 A61P11/00 A61P23/00  
A61P25/06 A61P1/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, PASCAL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 02 50021 A (BOX DAVID ;MOORE REBECCA (GB); COLCLOUGH DAVID (GB); GILLIES IAIN) 27 June 2002 (2002-06-27) page 8, line 1 - line 2 page 2, line 15-23 page 6, line 27-35 -----	1-5, 9-15
X	WO 98 30537 A (BEAMS RICHARD MANSFIELD ;DRYSDALE MARTIN JAMES (GB); HODSON HAROLD) 16 July 1998 (1998-07-16) page 7, line 11 -page 8, line 9 -----	1-15

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

14 October 2003

Date of mailing of the international search report

03/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Albayrak, T

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/06465

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0250021	A	27-06-2002	AU 2225202 A	01-07-2002
			CA 2432121 A1	27-06-2002
			WO 0250021 A1	27-06-2002
			NO 20032835 A	15-08-2003
-----				
WO 9830537	A	16-07-1998	AT 209183 T	15-12-2001
			AU 723095 B2	17-08-2000
			AU 6208398 A	03-08-1998
			BR 9806870 A	18-04-2000
			CN 1249744 T	05-04-2000
			CZ 9902483 A3	15-12-1999
			DE 69803272 D1	21-02-2002
			DE 69803272 T2	18-07-2002
			DK 958277 T3	18-02-2002
			EA 2033 B1	24-12-2001
			EE 9900281 A	15-02-2000
			WO 9830537 A1	16-07-1998
			EP 0958277 A1	24-11-1999
			ES 2168737 T3	16-06-2002
			HK 1021531 A1	15-03-2002
			HU 0001539 A2	28-11-2000
			JP 3251301 B2	28-01-2002
			JP 2000504041 T	04-04-2000
			NO 993429 A	12-07-1999
			NZ 336379 A	26-01-2001
			PL 334368 A1	28-02-2000
			PT 958277 T	31-05-2002
			SI 958277 T1	30-06-2002
			SK 93399 A3	13-03-2000
			TR 9901680 T2	21-09-1999
			TW 502010 B	11-09-2002
			US 6369272 B1	09-04-2002
			ZA 9800179 A	09-07-1999
-----				